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Function, information, and 
contributions: An evaluation of 
national multidisciplinary team 
meetings for rare cancers
Linn Rosell1,2, Jessica Wihl1,3, Oskar Hagberg1,  
Björn Ohlsson1 and Mef Nilbert2,4,5
Abstract
National virtual multidisciplinary team meetings have been established in Swedish cancer care in response to centralized 
treatment of rare cancers. Though national meetings grant access to a large multidisciplinary network, we hypothesized 
that video-based meetings may challenge participants’ contributions to the case discussions. We investigated 
participants’ views and used observational tools to assess contributions from various health professionals during the 
multidisciplinary team meetings. Data on participants’ views were collected using an electronic survey distributed to 
participants in six national multidisciplinary team meetings for rare cancers. Data from observations were obtained 
from the multidisciplinary team meetings for penile cancer, anal cancer, and vulvar cancer using the standardized 
observational tools Meeting Observational Tool and Metric of Decision-Making that assess multidisciplinary team meeting 
functionality and participants’ contributions to the case discussions. Participants overall rated the multidisciplinary team 
meetings favorably with high scores for development of individual competence and team competence. Lower scores 
applied to multidisciplinary team meeting technology, principles for communicating treatment recommendations, and 
guidelines for evaluating the meetings. Observational assessment resulted in high scores for case histories, leadership, 
and teamwork, whereas patient-centered care and involvement of care professionals received low scores. National 
virtual multidisciplinary team meetings are feasible and receive positive ratings by the participants. Case discussions 
cover medical perspectives well, whereas patient-centered aspects achieve less attention. Based on these findings, 
we discuss factors to consider to further improve treatment recommendations from national multidisciplinary team 
meetings.
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Case discussions in multidisciplinary team meetings 
(MDTMs) represent a focal point of the patient trajectory. 
Based on all relevant information available, a multidiscipli-
nary and multiprofessional team of experts consider treat-
ment alternatives and provide treatment recommendations 
based on the best evidence available. MDTMs have been 
found to be particularly relevant and beneficial in complex 
cases, where multidisciplinary case discussions have been 
reported to alter the treatment recommendation in up to 
one-third of the cases.1–3 Benefits linked to MDTMs include 
better coordination of care, development of clinical skills, 
and adherence to evidence-based treatment recommenda-
tions.4–8 Rare cancers are, as a group, associated with mul-
tiple challenges including late and incorrect diagnosis, 
adverse outcomes, limited clinical expertise, weak evi-
dence for best practice, and difficulties in collecting large 
series for research and in carrying out clinical trials.9
In Sweden, with a population of 10 million, surgery and 
select oncologic treatments for rare cancers, during recent 
years, been centralized to national specialist centers. This 
development was motivated by needs related to equal 
access to high-quality care, adherence to national treatment 
guidelines, infrastructures for research, and patient access 
to clinical trials. Between 2015 and 2017, treatment for 
penile cancer, anal cancer, vulvar cancer, gastroesophageal 
cancer, hepatobiliary cancer, and cytoreductive surgery 
with hyperthermic intraperitoneal chemotherapy (HIPEC) 
underwent such centralization. As part of this process, 
national virtual MDTMs were developed to grant high-
quality expert opinion and coordinated treatment recom-
mendations across geographical areas, and case discussion 
herein were made mandatory. In 2017, a national MDTM 
was also initiated for childhood cancer with treatment 
responsibility from six regional pediatric oncology 
centers.
Efficient MDTM structures are influenced by a number 
of factors such as case selection, access to relevant infor-
mation, technical equipment, participation from qualified 
experts, defined roles and responsibilities, leadership and 
teamwork, patient-centered care, and coordination of post-
MDTM work.10 Despite general agreement on the charac-
teristics of an effective MDTM, teams show considerable 
variability related to, for example, organization, case selec-
tion, and decision-making processes.11,12 This variability 
and different cultures and traditions can be expected to be 
particularly challenging when MDTM teams in different 
geographical locations are brought together as virtual teams 
in national networks, which is the case in the newly estab-
lished MDTMs for rare cancers in Swedish healthcare. We 
hypothesized that video-based meetings may challenge 
participants’ contributions to the case discussions. We, 
therefore, investigated participants’ experiences from 
virtual national MDTMs and assessed how different health 
professionals contributed the discussions and to what 
degree various disease-related and patient-related aspects 
were covered in the case discussions.
Materials and methods
Study design
With a focus on national virtual MDTMs for rare cancers, 
this study investigates health professionals’ views using an 
electronic questionnaire and through observational assess-
ment evaluates MDTM function and participants’ contribu-
tions to the case discussions.
Setting
In Sweden, treatment for several rare cancers was central-
ized during 2015–2017 to two to four treatment centers. 
The type of treatment centralized was defined for each 
cancer type, but, in general, involved curative surgical and/
or oncological treatment. Patients with palliative needs 
should, as far as possible, be treated in their local or 
regional hospitals, but should still be discussed at the rel-
evant national MDTM at the time of diagnosis and when 
otherwise relevant for treatment recommendations. Case 
discussions should, according to the national standards of 
cancer care, be performed at the time of primary diagnosis 
and at the time of potential recurrence. These standards 
also define participating health expertise, which for anal 
cancer include surgeon, oncologist, radiologist, nuclear 
therapist, coordinator, contact nurse, and, when relevant, 
pathologist. The MDTMs are connected through a national 
video-conferencing platform. Members of the national 
expert teams are default participants, and responsible clini-
cians in regional hospitals may participate for select cases 
for which they are responsible or have referred. The lead-
ership rests with the responsible physicians, which for the 
MDTMs included surgeons or oncologists. The national 
MDTM is coordinated from one of the national treatment 
centers, with annual rotating leadership among the two to 
four centers responsible. Sweden does not yet have a 
national formally implemented system for follow-up or 
evaluation of MDTMs.
Participants
All national MDTM teams for rare cancers in Sweden were 
eligble for the study. These included MDTMs for penile 
cancer, anal cancer, vulvar cancer, childhood cancer, 
cytoreductive surgery, advanced esophageal cancer, and 
hepatobiliary cancer. The latter MDTMs were grouped in 
the analyses motivated by a high degree of overlapping 
participants.
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Questionnaire
Participants in the national MDTMs received a link by 
email to an online, SurveyMonkey-based, questionnaire 
designed by the study group. Two reminders were sent. 
Data were collected between May 2017 and May 2018. 
The responders were asked to rate 14 aspects of the 
national MDTM they participated in on a 7-point Likert-
type scale (7 corresponded to fully agree and 1 to disa-
gree). The questionnaire was distributed to 241 participants 
in MDTMs for penile cancer (n = 33), anal cancer (n = 30), 
vulvar cancer (n = 26), childhood cancer (n = 53), cytore-
ductive surgery (n = 12), and advanced esophageal and 
hepatobiliary cancer (n = 87). In total, 125 (52%) health 
professionals responded and included 45% women with 
38% of the responders being above the age of 50. Among 
the respondents, physicians accounted for 87%, nurses for 
11%, and medical secretaries for 2%. The respondents’ 
disciplines were surgery (56%), medicine/oncology 
(26%), pediatric oncology (10%), radiology (6%), and 
pathology (2%).
Observations
In the observational part of the study, members of the 
study group used observational evaluation tools. 
Motivated by well-established meeting structures, weekly 
MDTMs, and sufficient patient volumes, the MDTMs for 
penile cancer, anal cancer, and vulvar cancer were selected 
for this part of the study. The MDTM for penile cancer 
had participation from the two national centers, lasted a 
mean of 30 min, had a mean of 19 (15–22) participants, 
and discussed a mean of 11 (10–14) cases. The MDTM for 
anal cancer had four participating centers, lasted 40 min, 
had a mean of 21 (18–25) participants, and discussed a 
mean of 5 (4–6) cases. The MDTM for vulvar cancer had 
four participating centers, lasted 40 min, had a mean of 20 
(15–25) participants, and discussed a mean of 6 (6) cases. 
Each MDTM was observed at three distinct occasions 
with participation from two study group members (M.N., 
B.O., J.W., and N.A. who are MDs) to a total of six obser-
vations for each MDTM. The observers independently 
rated the national MDTMs using the standardized obser-
vational tools: Meeting Observational Tool (MDT-MOT) 
and Metric of Decision-Making (MDT-MODe).13,14 MDT-
MOT assesses overall meeting performance to support 
team development based on evaluation of 10 key domains 
including attendance, leadership and chairing, teamwork 
and culture, personal development and training, physical 
environment, technology and equipment, organization 
and administration, post-meeting coordination, patient-
centered care, and clinical decision-making processes. 
These domains are evaluated using a 5-point Likert-type 
scale in which 5 implies optimal function and 1 implies 
insufficient function.13 MDT-MODe evaluates the MDTM 
based on individual assessment of each case discussion 
using a 5-point Likert-type scare in which 5 implies opti-
mal function and 1 implies insufficient function.14 MDT-
MODe is divided into two categories: availability of 
information (case history, patients’ view, psychosocial 
aspects, comorbidity, radiological, and pathological infor-
mation) and paticipants’ (including chair, surgeons, physi-
otherapist, oncologists, radiologists, pathologists, nurses, 
and MDTM coordinators) contributions to the case dis-
cussions.15 Prior to scoring, the observers read relevant 
publications and received oral information about the tools. 
Data using the MDT-MOT were collected from nine 
MDTMs, and data using the MDT-MODe were based on 
67 case discussions.
Ethics
All data were handled anonymously and are presented at 
group level. The study was ethically reviewed and granted 
permission by the regional ethics committee at Lund 
University (registration number: 2016/195).
Statistical analysis
Participants’ response profiles based on Likert-type scale 
data and overall data from the instruments MDT-MOT and 
MDT-MODe are presented as diverging stacked bar charts. 
Data from MDT-MOT and MDT-MODe were analyzed for 
inter-observer variability using correlation coefficient esti-
mates. For MDT-MOT, the total meeting score from each 
partipant was used. For MDT-MODe, inter-observer varia-
bility was estimated for each aspect based on all cases 
rated, followed by a total estimate of inter-observer varia-
bility for the tool as a whole. The mean score from the two 
observers for each aspect were evaluated and used in fur-
ther analyses, which motivates use of 0.5 intervals in the 
stacked bar charts. Statistical analyses were performed in R 
version 3.2.2.
Results
Evaluation of participants’ views
The response profiles from the 125 participants in the six 
national Swedish MDTMs for rare cancers are presented in 
Figure 1. Strongly affirmative scores (5–7) related to my 
role at the MDTM is clear (85%), MDTM develops team 
competence (81%), and MDTM develops individual compe-
tence (80%). The statements that received the lowest degree 
of agreement (scores 1–3) were guidelines for documenta-
tion of treatment recommendations are clear (20%), tech-
nology is well-functioning (22%), and we evaluate working 
with the MDTM (30%).
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Observational assessment
MDT-MOT is based on six observations from each diagno-
sis, whereas MDT-MODe is based on the total number of 
cases in the total number of case discussions observed, 
which was 68 for penile cancer, 30 for anal cancer, and 36 
for vulvar cancer. The mean scores from MDT-MOT and 
MDT-MODe observations were used in the further analyses. 
Inter-observer correlations were 0.71 for MDT-MOT and 
of 0.86 for MDT-MODe. MDT-MOT evaluates the MDTM 
as a whole. High scores were obtained for clinical decision-
making processes, teamworking and culture, technology 
and equipment, physical environment, and leadership and 
chairing. Low scores applied to patient-centered care, 
organization, administration, and post-meeting coordina-
tion (Figure 2, Supplementary Table 1).
MDT-MODe evaluates each case discussion and consid-
ers availability of information and paticipants’ contributions 
to the case discussions. Case information and case discus-
sions by the chair, surgeons, and oncologists scored high, 
whereas lower scores applied to radiologists, pathologists, 
nurses, physiotherapists, and MDTM coordinators (Figure 3, 
Supplementary Table 1). Low scores applied to information 
on psychosocial aspects and patients’ views.
Comparison between participants’ views 
and observational tools
Based on questionnaire data, MDTM participants reported 
high scores, for example, development of team competence 
(81%), development of individual competence (80%), clear 
MDTM goals (78%), involvement in case discussions 
(78%), and well-functioning leadership (77%), which was 
in agreement with the results from the observational tools 
that showed favorable scores for leadership and charing, 
teamwork and culture, and personal development and train-
ing (Figures 1–3). The observational tools, however, dis-
criminated contributions from the different disciplines with 
high scores for participation from surgeons and oncologists 
and lower scores for radiologists and pathologists. Based 
on the MDT-MODe, contributions from nurses, physiother-
apists and MDTM coordinators received low scores.
Both observational tools suggested weak consideration 
of patient-related aspects such as patients’ preferences, 
comorbidity, and psychosocial aspects, which stand in con-
trast to the responses from the MDTM participants with 
79% providing affirmative responses to consideration of 
comorbidity and 71% reporting to consider patients’ per-
spectives. Better outcome based on observations than ques-
tionnaire data applied to functionality of technology and 
equipment that was rated high using observational tools, 
whereas affirmative scores (5–7) for technical functionality 
were given by 63% of the participants.
Discussion
Main findings
National virtual MDTMs for rare cancers have, during 
recent years, been implemented in Swedish cancer care. 
Figure 1. Participants’ (n = 125) views on structure and function of six national virtual MDTMs in cancer care.
Stacked bar chart based on 14 aspects scored on a 7-point Likert-type scale.
Rosell et al. 5
Our data suggest that case information, leadership, and 
teamwork are overall well-functioning, whereas contribu-
tions from nurses, physictherapists and coordinators to the 
case discussions and considerations of patients’ perspec-
tives are limited (Figures 1–3). In Sweden, the medical 
teams responsible for establishing national MDTMs had 
access to updated national standards of care and a video-
based communication platform, but otherwise implemented 
these virtual MDTMs independently and without formal-
ized leadership training, improvement programs, or struc-
tured evaluation plans.
Several instruments have been developed to assess and 
improve MDTM function, but there are no generally agreed 
measures or principles for MDTM evaluations. Available 
instruments include checklists (Multidisciplinary Team 
Quality Improvement Checklist (MDT-QuIC)), observation 
tools (Multidisciplinary Team Observational Assessment 
Rating Scale (MDT-OARS), MDT-MODe, MDT-MOT, 
and a tumor leadership assessment instrument (ATLAS)), 
and self-assessment instruments (Team Evaluation and 
ASSESSment Measure (TEAM) and Multidisciplinary 
Team Feedback for Improving Teamworking (MDT-FIT)).6,14,16,17 
Our application of MDT-MOT and MDT-MODe was moti-
vated by the wish to use two comparable instruments with 
somewhat different focus, that is, on overall function of the 
MDTM versus evaluation of the individual case discus-
sions. The focus on the quality of information, the contribu-
tions to the case discussions, and the overall functionality of 
the meetings provide a basis for future team-led improve-
ment programs. We demonstrate high inter-observer correla-
tion and observations that are largely in agreement between 
the two observational assessment tools applied (Figures 2 
and 3). MDT-MOT and MDT-MODe have been applied to 
MDTMs for different diagnoses.18–21 Our double readings 
resulted in inter-observer variabilities of 0.71 for MDT-
MOT and 0.86 for MDT-MODe, which fit well with the 
findings from Gandamihardja et al.,19 who applied the 
MDT-MODe to MDTM for breast cancer with reliability 
coefficients of 0.73–0.93.
Studies on virtual MDTMs are rare, but experiences 
from regional MDTMs that connect specialists and com-
munity physicians in a geographical area demonstrate gen-
eral satisfaction and suggest that virtual MDTMs are 
feasible and valuable.4,22 Development of individual- and 
team competence were two of the top-rated benefits among 
participants in national MDTMs (Figure 1). This suggests a 
potential to strengthen national professional networks, 
increase collaboration across geographical regions, support 
further education, and stimulate knowledge sharing, which 
has been documented in regional MDTMs.4,23,24 Access to 
relevant information and good teamwork with representa-
tion from all core disciplines have been identified as major 
determinants for reaching treatment recommendations at 
MDTMs.15,19,20,25 We did not observe difficulties in reach-
ing joint treatment recommendations, which may partly be 
explained by the large expert network available, well-func-
tioning leadership, and relatively few cases per MDTM 
with a mean of 3–8 min per case discussion.
The national Swedish MDTMs are planned for rotating 
leadership on an annual basis. Most MDTMs are led by 
surgeons, but rotating leadership that involves various dis-
ciplines and professions, for example, oncologists and spe-
cialist nurses, may be relevant to consider since experiences 
from other MDTMs suggest that this principle may improve 
Figure 2. Observational assessment data based on MDT-MOT.
Stacked bar chart showing the results from the MDTMs for anal cancer, penile cancer, and vulvar cancer; the MDT-MOT tool assesses overall 
meeting performance to support team development based on 10 key domains using a 5-point scale.
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teamwork and reduce potential conflicts.25,26 Formalized 
MDTM structures, definition of goals, and follow-up on 
implementation of treatment recommendations represent 
future focus areas.4 Initiatives such as regular performance 
review, self-assessment and feedback, and e-based team 
training have proven effective and would likely be relevant 
and feasible also for national geographically disparate 
teams.20
Biomedical elements have, in several MDTM settings, 
been shown to be better covered than psychosocial aspects, 
information on comorbidity, and patients’ views.13,19,27–29 A 
patient-centered approach is considered to be an important 
basis for individualized treatment recommendations14,23,24,30, 
and consideration of psychosocial aspects, comorbidities, 
and patients’ autonomy are recognized as pillars for an 
effective MDTM.28,31 Data based on participants’ ratings 
Figure 3. Observational assessment data based on MDT-MODe. Stacked-bar chart showing the results from the MDTMs for anal 
cancer, penile cancer, and vulvar cancer. Evaluation of (a) information and (b) contribution to the discussion. The MDT-MODe tool 
assesses quality of presented information and participants’ contribution to the case discussion using a 5-point scale.
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and data from our observations did, in this regard, differ 
with 71%–79% affirmative response among participants 
related to comorbidity and patients’ perspectives, whereas 
observations rated consideration of patient-related perspec-
tives low (Figures 1–3). Jalil et al.18 used the MDT-MODe 
tool to evaluate MDTMs for various cancer types, including 
urological, gastrointestinal, and head and neck cancers 
and reported scores comparable to ours for comorbidity 
(mean 2.6 vs 2.1), psychosocial considerations (1.5 vs 1.4), 
and patient view (1.6 vs 1.3). National MDTMs gather 
expertise that may be geographically far from the patient, 
which further underscores the need to ensure development 
of structures to grant consideration of patient perspectives.23,31 
Furthermore, focus on patients’ preferences, performance 
status and comorbidities has been shown to positively 
influence implementation of MDTM recommendations.15,27 
MDT-MODe suggested low contribution to the case 
discussions from nurses, physiotherapists, and MDTM 
coordinators with scores of 1.0–1.2 (Supplementary Table 
1). This observation is supported by other studies, several of 
which have also applied MDT-MODe.14,15,19,20,24,29 This 
shortcoming likely reflects the dominance of medical 
aspects over patient-related aspects in the case discussions. 
A weak focus on rehabilitation perspectives at MDTMs has 
been reported from the United Kingdom.15,29,31–33 Based on 
the National Ewing Sarcoma MDTM in the United 
Kingdom, Bate et al.32 have documented that patients feel 
that their views should inform the decision-making process 
and recommend initiatives such as treatment recommenda-
tions written in plain language and development of tools to 
improve patient involvement and enhance communication. 
Soukup et al.25 demonstrated that a complete patient profile 
and contributions to the case review by all core disciplines 
drive the decision-making process at MDTMs. Our 
Table 1. Guidelines for establishing and running a national virtual multidisciplinary team meeting.
Focus area Issues for consideration and planning
Principles for referral Definition of time points in the disease trajectory for case discussions at national MDTM
Establishment of guidelines for referral, for example, directly from local/regional hospital or from 
national expert center
Definition of referral format, including structure and content of case history and ancillary data format
Implementation of mechanism that allows identification of all eligible patients in participating clinics 
and hospitals
Implementation of a MDTM coordinator role for collection and review of all available information 
prior to the case discussion
Infrastructure and 
technology
Regular meeting times and an agreed time frame
Access to an interactive communication platform on which various types of documentation and 
information can be shared
An interconnected IT system that provides an overview of the information available
Access to technical support when relevant
Identifying and supporting 
chair and participants
Definition of required participants to grant qualified case discussions and recommendations
Selection of chair
Ensuring required expertise among participants
Clarification of participants’ roles with particular considerations of contributions from radiology, 
pathology, and care personnel
Defining relevant participation from ancillary expert areas such as molecular diagnostics, 
rehabilitation, and palliative care
Adjustment of work plans to allow case preparation, meeting participation, and relevant post-meeting 
work for participants
Running the meeting Principles for identification of all participants
Chairing that grants an efficient meeting structure and encourages active participation from all 
participants
Principles and responsibilities for documentation of case discussions and recommendations
Establishment of mechanism of how patients should be screened for eligibility of clinical trials
Responsibilities for communicating treatment recommendation to patients
Responsibilities for communicating treatment recommendation to other healthcare providers
Organizational and legal 
aspects
Applicable confidentiality agreements in place
Legal consideration of compliance with regulations for data transfer
Relevant funding and resources in place
Mandate to provide treatment recommendations across healthcare providers
Principles and methods to evaluate performance and improve MDTM functionality
Principles for follow up of adherence to referral principles from participating hospitals and regions
MDTM: multidisciplinary team meeting; IT: information technology.
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observations suggest that the national MDTM teams should 
discuss and consider how to grant an optimal balance 
between biomedical facts and patient-related aspects.23–25 
Development of standards for how patient perspectives are 
granted consideration would be relevant. Such a develop-
ment will likely require consideration of the current meeting 
format and should involve care professionals who may rep-
resent patients’ perspectives at the MDTM.
Since national MDTMs are resource demanding and 
require significant coordination, initiatives that grant safe 
and easy access to relevant information, skilled partici-
pants, well-functioning teamwork, good leadership, and 
efficient administrative routines are crucial.1,2,6,15 The 
extended number of participants from various hospitals 
with different routines and traditions adds a level of com-
plexity to national MDTMs. Though overall feasible, a 
number of issues should be considered prior to initiation 
of a national MDTM for best possible outcome. These 
include infrastructure and technology, referral principles, 
requirements for participants, running principles, respon-
sibilities for communicating recommendations, and prin-
ciples for governance and evaluation of national MDTMs. 
Based on our experiences and observations, and on cur-
rent literature, we summarized issues to consider into 
guidelines for virtual national MDTMs in cancer care 
(Table 1).
Strengths and limitations
We aimed to obtain a comprehensive picture rather than to 
perform detailed evaluations of the independent MDTMs. 
The combination of team members’ subjective views and 
objective evaluation based on observational tools represent 
strengths and allow for identification of areas of agreement 
as well as disagreement between the different measures. 
The concordant picture obtained for most factors and areas 
supports identification of relevant benefits and shortcom-
ings. We regard a Hawthorne effect as less likely since the 
observers were present at one participating hospital, 
whereas the majority of the participants participated by 
video from other hospitals. Limitations include a response 
rate of 52% for the electronic questionnaire and observa-
tions limited to three MDTM sessions for each diagnosis. 
Though the observers documented good inter-observer 
agreement between the MDT-MODe and the MDT-MOT, 
the tools were new to the study group, and the evaluators 
may still be in the learning curve. Furthermore, the tools do 
not allow for scoring of individual specialists and do not 
account for cases where, for example, histopathological 
input was not considered relevant. The low scores for the 
contribution from nurses, physiotherapists, and MDTM 
coordinators may not fully reflect a suboptimal involve-
ment, for example, limited involvement from nurses could 
reflect clinical trajectories where cases are discussed at the 
MDTM prior to being seen by the responsible nurse. Due to 
a limited number of answers from nurses and coordinators, 
subgroup analysis was not possible.
Conclusion
National virtual MDTMs for rare cancer type have success-
fully been established in Swedish cancer care. Evaluation 
based on participants’ views and structured observational 
assessment identified well-functioning leadership and 
teamwork, but revealed weaknesses related to patient per-
spectives, involvement of care professionals, and MDTM 
evaluation principles. To make best use of the expert net-
works involved in national MDTMs and to provide appro-
priate and acceptable treatment recommendations for 
patients with rare cancer type, we suggest that team review 
and MDTM evaluation should be prioritized with a specific 
focus on how patient perspectives and contributions from 
care personnel may be strengthened.
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